biotech · Major Depressive Disorder · Schizophrenia · NBIX
NEUROCRINE BIOSCIENCES
NEUROCRINE BIOSCIENCES INC
NEUROCRINE BIOSCIENCES is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker NBIX. Primary therapeutic focus areas include Major Depressive Disorder, Schizophrenia, Congenital Adrenal
6027 Edgewood Bend Ct, San Diego, California 92130, US HQ
1992 Founded
2,307 Employees
Public company Type
NBIX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 6027 Edgewood Bend Ct, San Diego, California 92130, US
- Founded
- 1992
- Employees
- 2,307
- Programs
- 79
- Drugs
- 28
- Patents
- 111
NBI-98854 50 mg capsule
Phase 1 · small molecule · Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
NBI-98854 50 mg capsule for Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects is a Phase 1 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Internal code NBI-98854-1303
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- NEUROCRINE BIOSCIENCES INC
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
- Status
- completed
- Trials
- 1